Thaum Lub Rau Hli 30, Avistone tus kheej tsim MET inhibitor Vebreltinib tau txais kev pom zoo los ntawm National Medical Products Administration (NMPA) ntawm Tuam Tshoj rau kev kho mob rau cov neeg mob uas muaj mob qog nqaij hlav hauv zos lossis metastatic non-small cell lung cancer (NSCLC) uas muaj MET amplification. Qhov no yog qhov kev pom zoo thib peb rau Vebreltinib hauv Tuam Tshoj thiab thawj zaug kev kho mob ib leeg hauv ntiaj teb uas tau pom zoo tshwj xeeb rau cov neeg mob NSCLC MET-amplified.
Kev pom zoo ntawm Vebreltinib hauv Suav teb rau qhov kev qhia tshiab no - kho cov neeg mob uas muaj mob qog nqaij hlav hauv lub ntsws uas tsis yog me me (NSCLC) uas muaj MET amplification - yog raws li cov txiaj ntsig zoo los ntawm Cohort 2 thiab Cohort 3 ntawm kev tshawb fawb KUNPENG (NCT04258033).
Pawg 2 feem ntau yog cov neeg mob uas tau kho mob yav dhau los uas muaj MET-amplified NSCLC uas tsis tau ua tiav kev kho mob tus qauv (xws li platinum-based chemotherapy), thaum Pawg 3 feem ntau suav nrog cov neeg mob uas tsis tau kho mob uas muaj MET-amplified NSCLC uas tsis kam kho chemotherapy.
Tag nrho muaj 86 tus neeg mob uas muaj NSCLC theem siab lossis theem nrab tau raug sau npe rau hauv ob pawg neeg mob (33 hauv Cohort 2 thiab 53 hauv Cohort 3). Cov txiaj ntsig ntawm kev tshawb fawb qhia tau tias tus nqi teb rov qab (ORR) ntawm 48.8%, tus nqi tswj kab mob (DCR) ntawm 77.9%, lub sijhawm teb nruab nrab (DoR) ntawm 12.1 lub hlis, lub sijhawm ciaj sia tsis muaj kev nce qib nruab nrab (PFS) ntawm 7.4 lub hlis, thiab lub sijhawm ciaj sia nruab nrab (OS) ntawm 13.9 lub hlis.
Hauv Cohort 2 (33 tus neeg mob uas tau kho ua ntej), ORR yog 48.5%, DCR yog 78.8%, DoR nruab nrab yog 11.0 lub hlis, PFS nruab nrab yog 6.2 lub hlis, thiab OS nruab nrab yog 11.7 lub hlis.
Hauv Cohort 3 (53 tus neeg mob uas tsis tau kho mob), ORR yog 49.1%, DCR yog 77.4%, DoR nruab nrab yog 12.1 lub hlis, PFS nruab nrab yog 8.3 lub hlis, thiab OS nruab nrab yog 15.5 lub hlis.
Hauv kev tshawb fawb KUNPENG, 21 tus neeg mob uas muaj cov qog nqaij hlav metastases hauv lub hlwb tau raug soj ntsuam los ntawm Pawg Neeg Saib Xyuas Kev Ywj Pheej (IRC). Ntawm cov no, 10 tau txais cov lus teb ib nrab (PR), ua rau ORR ntawm 47.6%, DCR ntawm 85.7%, thiab nruab nrab DoR ntawm 11.0 lub hlis. Tsis tas li ntawd, qhov nruab nrab PFS thiab OS yog 8.3 lub hlis thiab 14.7 lub hlis, raws li.
Tam sim no, tseem muaj ntau qhov kev sim tshuaj kho mob qog noj ntshav tshiab hauv Suav teb nrhiav cov neeg mob. Kev sab laj txog cov tshuaj tshiab thiab cov thev naus laus zis, koj tuaj yeem tiv tauj Beijing South Region Oncology Hospital International Department.
Xov Tooj: 4008803716
Email：myimmnet@163.com
Lub sijhawm tshaj tawm: Lub Xya Hli-08-2025